1. Introduction

Deep-Sea Organism Patent Rights concern the legal protection of inventions, discoveries, biological materials, genetic sequences, enzymes, microorganisms and biotechnology products obtained from organisms living in the deep ocean.

Deep-sea organisms include:

Hydrothermal vent bacteria and archaea.

Deep-sea fungi and marine microorganisms.

Bioluminescent organisms.

Deep-sea sponges and corals.

Marine extremophiles.

Deep-sea algae and microorganisms.

Organisms living in high-pressure, low-temperature and oxygen-deficient environments.

These organisms may contain unique biological properties useful in pharmaceuticals, cancer research, industrial enzymes, biotechnology, cosmetics, agriculture and environmental protection.

The central legal question is:

Can a researcher or biotechnology company obtain patent rights over an organism, its genetic material, or an invention developed from a deep-sea biological resource?

The answer depends on the distinction between discovering naturally occurring biological material and creating a genuinely new, inventive and industrially applicable invention.

Deep-sea patent rights also raise questions of marine sovereignty, access to genetic resources, benefit-sharing, biodiversity conservation, indigenous and national interests, and international intellectual-property protection.

2. Meaning and Scope of Deep-Sea Organism Patent Rights

A deep-sea organism patent is not necessarily a patent over the entire living organism. It may concern a particular technical invention derived from that organism.

For example:

A researcher discovers a bacterium near a hydrothermal vent.

The bacterium produces an enzyme that remains stable under extreme temperatures.

Researchers isolate the relevant enzyme and identify its industrial properties.

A company develops a technically improved enzyme-production process.

The company applies for a patent over the qualifying invention.

The patent may protect the engineered enzyme, a sufficiently novel composition, a specific production process or a particular technical application.

It does not automatically confer ownership over every naturally occurring example of the organism or its genetic information.

Important categories of patentable subject matter

3. International Legal Framework

A. Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)

The TRIPS Agreement establishes international minimum standards for patent protection.

Article 27(1) requires patents to be available for inventions in all fields of technology, provided they satisfy:

Novelty.

Inventive step.

Industrial applicability.

Article 27(2) allows countries to exclude inventions where preventing commercial exploitation is necessary to protect public order, morality, human, animal or plant life, health, or the environment.

Article 27(3)(b) permits specified exclusions for plants and animals, while requiring protection for microorganisms and microbiological processes, subject to the provision's terms.

Article 28 provides patent owners with exclusive rights to prevent unauthorized commercial exploitation of patented products and processes.

Legal significance: A company cannot obtain an international monopoly merely by discovering a deep-sea organism. It must establish a qualifying invention under the applicable national patent law.

B. United Nations Convention on the Law of the Sea (UNCLOS), 1982

The United Nations Convention on the Law of the Sea establishes the legal framework for ocean exploration and resource management.

Important provisions include:

Article 136 – Common Heritage of Mankind

The seabed and ocean floor beyond national jurisdiction, known as the Area, and its resources are the common heritage of mankind.

Article 137 – Legal Status of the Area and Its Resources

No State or natural or juridical person may claim or exercise sovereignty or sovereign rights over the Area or its resources contrary to the Convention.

An important qualification is necessary: Part XI's common-heritage regime specifically concerns the Area and its resources, particularly mineral resources. It should not automatically be treated as a complete legal ownership regime for all deep-sea genetic resources.

Article 241 – Non-recognition of Marine Scientific Research as a Basis for Claims

Marine scientific research activities cannot constitute the legal basis for claims to any part of the marine environment or its resources.

Article 192 – General Obligation

States must protect and preserve the marine environment.

Article 194 – Measures to Prevent Pollution

States must take measures to prevent, reduce and control marine pollution.

These provisions become important when commercial biotechnology companies collect microorganisms from deep-sea ecosystems.

C. Convention on Biological Diversity (CBD), 1992

The Convention on Biological Diversity establishes three objectives:

Conservation of biological diversity.

Sustainable use of biological resources.

Fair and equitable sharing of benefits arising from genetic resources.

Articles 15 and 16 are particularly relevant.

Article 15 recognizes national sovereignty over natural resources and establishes principles governing access to genetic resources.

Article 16 addresses access to and transfer of biotechnology, including intellectual-property-related considerations.

The CBD framework generally concerns biological resources within the jurisdictional scope of the Convention. It does not itself provide a comprehensive access-and-benefit-sharing regime for marine genetic resources in areas beyond national jurisdiction.

D. Nagoya Protocol, 2010

The Nagoya Protocol regulates access to genetic resources and the fair and equitable sharing of benefits arising from their utilization.

Its principal requirements include:

Prior informed consent where applicable.

Mutually agreed terms.

Benefit-sharing arrangements.

Compliance measures.

Recognition of applicable domestic access legislation.

For example, if a biotechnology company collects a marine microorganism from a country's exclusive economic zone, domestic access-and-benefit-sharing requirements may apply.

However, the Nagoya Protocol does not directly govern genetic resources collected in areas beyond national jurisdiction merely because they are marine organisms.

E. Biodiversity Beyond National Jurisdiction (BBNJ) Agreement, 2023

In force since 17 January 2026

The BBNJ Agreement is particularly important for deep-sea genetic resources.

It addresses marine biological diversity in areas beyond national jurisdiction, including the high seas and the international seabed.

Its Part II concerns marine genetic resources, including digital sequence information associated with such resources.

Its major objectives include:

Fair and equitable sharing of benefits.

Scientific cooperation.

Capacity-building.

Access to marine scientific information.

Technology transfer.

Notification and traceability of relevant research activities.

The Agreement defines utilization broadly to include research and development on the genetic and biochemical composition of marine genetic resources, including biotechnology.

It establishes a framework for notifications through the Clearing-House Mechanism and benefit-sharing arrangements.

Relationship with patents: The BBNJ Agreement does not simply prohibit patents on inventions developed from deep-sea organisms. Rather, it establishes additional international obligations concerning the utilization and sharing of benefits from marine genetic resources in areas beyond national jurisdiction. Patent rights and benefit-sharing obligations must therefore be considered separately.

Sources: UN and IMO explanations of the Agreement's entry into force.

International Maritime Organization+2

4. Patentability Requirements for Deep-Sea Organisms

A patent application based on deep-sea biological material must satisfy the relevant national patentability requirements.

4.1 Novelty

The claimed invention must be new.

If a deep-sea bacterium has already been publicly described in scientific literature, a subsequent applicant cannot ordinarily patent the naturally occurring bacterium simply by rediscovering it.

However, a new genetically modified version or a genuinely novel technical process may qualify.

4.2 Inventive Step

The invention must not be obvious to a person skilled in the relevant scientific field.

For example, merely extracting a known marine enzyme using an established procedure may not satisfy the inventive-step requirement.

A technically unexpected modification that substantially improves enzyme stability under extreme pressure may potentially satisfy it.

4.3 Industrial Applicability

The invention must have a practical industrial application.

Examples include:

Enzymes for pharmaceutical manufacturing.

Microorganisms for oil-spill treatment.

Industrial biotechnology processes.

New compounds for drug development.

Biological processes for environmental remediation.

4.4 Sufficient Disclosure

The patent application must describe the invention sufficiently to enable a skilled person to perform it.

This is especially important for deep-sea microorganisms because their identification, biological characteristics and reproducibility may present technical difficulties.

Where required, applicants may need to deposit microorganisms with a recognized international depositary authority under applicable patent-deposit rules.

4.5 Biological Material and Genetic Sequence Disclosure

A patent applicant must comply with the disclosure requirements of the relevant jurisdiction.

Important information may include:

Scientific identification of the organism.

Geographical source of the material.

Collection location and circumstances.

Genetic sequence information.

Method of isolation.

Relevant biological characteristics.

Details of any genetic modification.

The WIPO materials explain that countries have adopted different approaches to disclosure of genetic-resource origins in patent applications.

WIPO+2

5. Important Case Laws

There is no universally recognized leading judgment establishing a comprehensive patent-ownership regime specifically for deep-sea organisms. However, several biotechnology and biological-invention judgments establish principles directly relevant to deep-sea patent applications.

Case 1: Diamond v. Chakrabarty (1980)

Citation: 447 U.S. 303 (1980).

United States Supreme Court

Facts:

Ananda Chakrabarty developed a genetically engineered bacterium capable of breaking down multiple components of crude oil.

The patent application claimed the genetically modified bacterium and related inventions.

The patent examiner initially rejected the organism claims on the ground that living organisms were not patentable subject matter.

Judgment:

The US Supreme Court held that a human-made, genetically modified microorganism could constitute patentable subject matter.

The Court distinguished a naturally occurring organism from a microorganism created through human intervention.

Legal principle:

A genetically engineered microorganism may be patentable where it possesses characteristics resulting from human ingenuity rather than merely existing in nature.

Application to deep-sea organisms:

Suppose a scientist discovers a deep-sea bacterium that naturally produces an enzyme capable of surviving extreme temperatures.

The naturally occurring bacterium cannot automatically be patented.

However, a genetically engineered version with genuinely new technical characteristics may qualify for patent protection.

LII / Legal Information Institute

Case 2: Funk Brothers Seed Co. v. Kalo Inoculant Co. (1948)

Citation: 333 U.S. 127 (1948).

United States Supreme Court

Facts:

The dispute concerned a mixture of naturally occurring bacteria used to inoculate leguminous plants.

The inventor had discovered that certain bacterial strains could coexist without inhibiting each other.

Judgment:

The Supreme Court rejected the patent claim because the bacteria retained their natural characteristics and the combination did not produce a sufficiently inventive result.

Legal principle:

A mere discovery of natural biological properties or the combination of naturally functioning organisms does not automatically constitute a patentable invention.

Application:

A researcher cannot necessarily obtain a patent merely by combining several naturally occurring deep-sea microorganisms that continue performing their ordinary biological functions.

A genuinely new technical effect or inventive modification must be demonstrated.

Case 3: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Citation: 569 U.S. 576 (2013).

United States Supreme Court

Facts:

Myriad Genetics obtained patents concerning BRCA1 and BRCA2 genes associated with breast and ovarian cancer risks.

The dispute concerned whether isolated naturally occurring DNA sequences could be patented.

Judgment:

The Supreme Court held that naturally occurring DNA does not become patentable merely because it has been isolated from the surrounding genetic material.

However, complementary DNA (cDNA) could generally qualify because it is created through human intervention, subject to applicable patentability requirements.

Legal principle:

Discovery and isolation of a naturally occurring genetic sequence are not equivalent to creating a patentable invention.

Application:

A biotechnology company discovering a unique genetic sequence in a deep-sea organism cannot automatically claim exclusive patent ownership over that naturally occurring sequence.

A genuinely synthetic genetic construct or engineered biological application may receive different treatment.

Case 4: Harvard College v. Canada (Commissioner of Patents) (2002)

Citation: 2002 SCC 76.

Supreme Court of Canada

Facts:

The case concerned the patentability of a genetically modified mouse known as the Harvard Oncomouse, developed for cancer research.

The patent application involved a living animal genetically modified to develop cancer more readily.

Judgment:

The Supreme Court of Canada refused the patent claim to the higher life form under the Canadian Patent Act.

Legal principle:

The patentability of living organisms depends on the wording of the applicable national patent statute. A patentable genetic modification does not necessarily make the entire organism patentable.

Application:

A genetically modified deep-sea animal may face different legal treatment from an engineered microorganism or a modified enzyme.

Case 5: Dimminaco A.G. v. Controller of Patents and Designs (2002)

Citation: 2002 IPLR 255 (Cal).

Calcutta High Court, India

Facts:

The applicant sought patent protection for a process of preparing an infectious bursitis vaccine involving a live virus.

The patent authority refused the application because the resulting product contained a living organism.

Judgment:

The Calcutta High Court rejected the proposition that a process must be unpatentable merely because its final product contains a living organism.

It recognized that a process producing a commercially useful product containing a living organism could qualify as an invention.

Legal principle:

The presence of a living organism in a manufactured product does not, by itself, prevent patent protection for a qualifying manufacturing process.

Application:

An Indian biotechnology company developing a novel process to manufacture a pharmaceutical enzyme using a deep-sea microorganism may seek patent protection, provided all statutory requirements are satisfied.

Ali on Patents

Case 6: Nuziveedu Seeds Ltd. v. Monsanto Technology LLC (2018)

Citation: 2018 SCC OnLine Del 10236 (Delhi High Court Division Bench).

Delhi High Court

Facts:

The litigation concerned patent protection for genetically modified cotton technology and the relationship between patent rights and plant-variety legislation.

Judgment:

The Delhi High Court considered the scope of Section 3(j) of the Indian Patents Act and the exclusion of plants, plant parts, seeds and essentially biological processes.

It recognized that microorganisms are not expressly included in the microorganism exclusion from patentability under Section 3(j).

Legal principle:

Microorganisms and plant varieties must be treated according to the specific statutory language governing their patentability.

Application:

The case is relevant to deep-sea microorganisms because Indian law distinguishes microorganisms from plants and animals for purposes of patent eligibility.

However, the case does not establish that every naturally isolated marine microorganism is patentable.

Indian Kanoon+1

6. Deep-Sea Organism Patent Rights Under Indian Law

India has several legal instruments relevant to deep-sea biological resources and biotechnology inventions.

A. Indian Patents Act, 1970

The following provisions are particularly important.

Section 2(1)(j): Invention

An invention must satisfy the statutory definition of a new product or process involving an inventive step and capable of industrial application.

Section 3(c): Discovery of Natural Living Things

The mere discovery of a living thing occurring in nature is not an invention.

Therefore, merely discovering a new deep-sea bacterium does not automatically create patent rights.

Section 3(j): Plants, Animals and Microorganisms

Plants and animals, in whole or in part, are excluded from patentability, subject to the statutory exception for microorganisms.

This distinction is important for marine biotechnology.

Section 10: Contents of Patent Specification

The patent specification must adequately describe the invention and explain how it can be performed.

Section 25: Opposition to Patent

A patent application or granted patent may be challenged on statutory grounds, including:

Lack of novelty.

Lack of inventive step.

Insufficient disclosure.

Incorrect disclosure of the source or geographical origin of biological material.

Prior knowledge available within local or indigenous communities.

These provisions are important safeguards against inappropriate claims over biological resources.

Government of India+1

B. Biological Diversity Act, 2002

The Biological Diversity Act, 2002 regulates access to biological resources and associated benefit-sharing arrangements.

Important provisions include:

Section 3: Regulates specified activities involving Indian biological resources by persons and entities covered by the provision.

Section 6: Regulates applications for intellectual-property rights based on biological resources accessed from India.

Section 7: Provides for prior intimation to the State Biodiversity Board for specified persons and activities, subject to statutory exceptions.

Section 18: Establishes functions of the National Biodiversity Authority.

Section 21: Deals with equitable benefit-sharing arrangements.

The 2023 amendment changed certain compliance requirements. Accordingly, the applicable approval, registration or benefit-sharing procedure must be assessed under the amended legislation and relevant rules.

Example:

An Indian biotechnology company collects microorganisms from Indian marine waters and develops a pharmaceutical product.

Depending on the company's legal status, the source of the biological resource and the nature of its activities, it may need to comply with National Biodiversity Authority requirements before obtaining or commercializing relevant intellectual-property rights.

Section 6 specifically addresses intellectual-property applications based on biological resources accessed from India.

IndiaCode

C. National Biodiversity Authority (NBA)

The National Biodiversity Authority plays an important role in regulating access to biological resources and benefit-sharing.

Its functions include:

Regulating specified access to biological resources.

Examining relevant intellectual-property applications.

Facilitating benefit-sharing arrangements.

Protecting biodiversity-related interests.

Supporting conservation and sustainable utilization.

For deep-sea resources within India's jurisdiction, the applicable Indian biodiversity legislation is particularly relevant.

D. Indian Marine and Deep-Sea Research

India's deep-sea research activities are also relevant to patent ownership and access regulation.

For example, research involving deep-sea microorganisms, marine enzymes and genetic materials may create patentable inventions.

However, the researcher or institution must distinguish between:

Ownership or lawful possession of collected biological samples.

Rights to conduct research on the samples.

Patent rights over resulting inventions.

Obligations to share benefits under applicable biodiversity laws.

These are separate legal questions.

7. Ownership Disputes Over Deep-Sea Genetic Resources

One of the most difficult legal questions is determining who has the right to control genetic resources collected from international waters.

Consider the following hypothetical situation:

A biotechnology company from Country A sends a research vessel to a hydrothermal vent located in an area beyond national jurisdiction.

Its scientists collect a previously uncharacterized microorganism.

The company subsequently identifies a biochemical compound that may be useful in cancer treatment.

It develops a modified version and obtains a patent in Country A.

Several legal issues arise:

First: Collection rights

Was the collection consistent with applicable international law and the BBNJ Agreement?

Second: Patent ownership

Does the company own the qualifying invention under the patent law of Country A?

Third: Benefit-sharing

Are the research and commercial activities subject to the BBNJ Agreement's benefit-sharing arrangements?

Fourth: Environmental responsibility

Did the collection or research damage a vulnerable deep-sea ecosystem?

Fifth: International equity

Should other countries have access to research information, scientific knowledge and benefits arising from the commercial exploitation?

The BBNJ Agreement provides a framework for addressing these questions, but patent ownership and international benefit-sharing remain legally distinct.

8. Major Legal Challenges

8.1 Biopiracy

Biopiracy occurs when biological resources or associated traditional knowledge are commercially exploited without appropriate authorization or benefit-sharing.

For example, a foreign company might collect biological material from a country's marine territory, develop a commercial product and seek patent protection without satisfying applicable access requirements.

8.2 Patent Monopolization

A broad patent claim might restrict competing researchers from using a particular engineered enzyme or technical process.

The law must distinguish legitimate protection of inventions from attempts to monopolize naturally occurring biological information.

8.3 Digital Sequence Information

Deep-sea genetic research increasingly relies on digital sequence information (DSI).

A researcher may obtain genetic sequence data from a publicly accessible database without physically collecting the original microorganism.

This raises questions concerning:

Traceability.

Attribution.

Commercial utilization.

Benefit-sharing.

Research transparency.

The BBNJ Agreement specifically addresses DSI associated with marine genetic resources within its scope.

9. Relationship Between Patent Rights and Benefit-Sharing

Patent protection and benefit-sharing are not mutually exclusive.

A biotechnology company may hold a valid patent while remaining subject to separate legal obligations concerning the biological resources used to develop its invention.

Consider this example:

Hypothetical deep-sea biotechnology project

Resource collection

A research institution collects microorganisms from an international deep-sea hydrothermal vent.

Scientific research

Scientists identify an unusual enzyme capable of functioning under extreme environmental conditions.

Technological development

Researchers engineer the enzyme to improve its industrial performance.

Patent application

The institution applies for protection of the qualifying engineered enzyme and production process.

Commercialization

A pharmaceutical or industrial biotechnology company licenses the invention.

Benefit-sharing

Applicable international and domestic obligations concerning research information, technology transfer and monetary benefits are fulfilled.

Legal outcome: A patent may protect the qualifying technological invention without giving the patent holder unrestricted ownership of the original deep-sea ecosystem or all naturally occurring organisms of that type.

10. International Legal and Policy Recommendations

Several reforms can improve the regulation of deep-sea organism patents.

1. Mandatory genetic-resource disclosure

Patent applicants should provide appropriate information about the source and geographical origin of biological material.

2. Stronger patent examination

Patent authorities should carefully examine claims involving naturally occurring organisms, genetic sequences and biological discoveries.

3. Transparent benefit-sharing

Commercial users should comply with applicable monetary and non-monetary benefit-sharing arrangements.

4. Improved international databases

Patent offices and biodiversity authorities should cooperate to identify previously documented marine organisms and genetic sequences.

5. Protection of deep-sea ecosystems

Bioprospecting should be consistent with environmental conservation and applicable environmental impact assessment obligations.

6. International scientific cooperation

Developing countries should have meaningful opportunities to participate in marine genetic research and access scientific knowledge and technology.

7. Responsible commercialization

Companies should distinguish patentable technical inventions from the biological resources and genetic information on which those inventions depend.

11. Conclusion

Deep-Sea Organism Patent Rights represent an important intersection of intellectual-property law, international marine law, biotechnology regulation and biodiversity conservation.

The central legal principle is that the discovery of a naturally occurring deep-sea organism does not automatically create patent ownership over that organism.

However, a genuinely new genetically modified microorganism, engineered enzyme, synthetic biological construct or inventive manufacturing process may qualify for patent protection if it satisfies the applicable statutory requirements.

The judgments in Diamond v. Chakrabarty, Funk Brothers, Myriad Genetics, Harvard College v. Canada, Dimminaco and Nuziveedu Seeds v. Monsanto provide important guidance on biological inventions and patent eligibility.

The BBNJ Agreement, which entered into force on 17 January 2026, adds an important international framework for marine genetic resources in areas beyond national jurisdiction.

Ultimately, the legal challenge is to balance three interests:

Innovation: Protecting genuine scientific and technological inventions.

Equity: Ensuring fair and equitable sharing of benefits from marine genetic resources.

Conservation: Protecting deep-sea biodiversity for present and future generations.

12. Important Legal References for Further Research

Useful authoritative research sources:

WIPO – Debated Heroes from the Deep Sea

United Nations – BBNJ Agreement

Indian Patent Office

Convention on Biological Diversity

UNCLOS – Full Text

Research note: The cited judgments establish general biotechnology patent principles; they should not be interpreted as direct judicial decisions on ownership of deep-sea genetic resources. The applicable result depends on the location of collection, the nature of the biological material, the claimed invention and the relevant national and international legal obligations.